Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 9Terminated 6Recruiting 6Withdrawn 2Active not recruiting 2Unknown 1Suspended 1Not yet recruiting 1No longer available 1

Sponsor Class

NIH 3OTHER 2INDUSTRY 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Lymphoid 6Head & Neck 6Thoracic 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 306Lymphoma, Non-Hodgkin 227Lymphoma, Large B-Cell, Diffuse 220Lymphoma, Follicular 201Leukemia, Lymphocytic, Chronic, B-Cell 168Lymphoma, B-Cell 147Recurrence 124Burkitt Lymphoma 117Lymphoma, Mantle-Cell 112Leukemia, Myeloid, Acute 106Leukemia 103Hodgkin Disease 102Multiple Myeloma 95Lymphoma, B-Cell, Marginal Zone 87Neoplasms 80Myelodysplastic Syndromes 69Lymphoma, T-Cell, Peripheral 62Hematologic Neoplasms 61Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 58Lymphoma, T-Cell 52Lymphoma, T-Cell, Cutaneous 44Waldenstrom Macroglobulinemia 41Leukemia, Biphenotypic, Acute 35Mycosis Fungoides 31Lymphoproliferative Disorders 30Leukemia, B-Cell 30Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Breast Neoplasms 28Myeloproliferative Disorders 26

Interventions

Cyclophosphamide 2pomalidomide 1fludarabine 1Vincristine 1Rituximab 1Prednisone 1Nivolumab 1Etoposide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Epstein-Barr Virus Infections × Lymphoid × Clear all
NCT03258567 2026-06-05

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT00032513 2026-06-01

Genetic Studies of Chronic Active Epstein-Barr Disease

National Institutes of Health Clinical Center (CC)

Recruiting
300 enrolled
Lymphoid

Herpes Simplex, Infectious Mononucleosis, Lymphoproliferative Disorders, Virus Diseases, Epstein-Barr Virus Infections

NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT03394365 2026-05-22

ALLELE

Pierre Fabre Medicament

Phase 3 Recruiting
115 enrolled
Lymphoid

Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT04664179 2025-12-12

CILESTE

Baylor College of Medicine

Phase 1 Recruiting
52 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Epstein-Barr Virus Infections

NCT06224049 2024-03-12

GI-hNeoT-01

BGI, China

Phase EARLY_PHASE1 Recruiting
6 enrolled
Lymphoid

Lymphoma, T-Cell, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡